ARAMON: A phase 2, randomized, open-label study comparing darolutamide (DARO) vs enzalutamide (ENZA) monotherapy on serum testosterone levels in patients (pts) with castration-sensitive prostate cancer (CSPC) after biochemical recurrence (BCR) Meeting Abstract

  

Authors:	Laccetti, A. L.; Smith, M. R.; Scher, H. I.; Verholen, F.; Adorjan, P.; Dissanayake, M.; Gao, X.
Abstract Title:	ARAMON: A phase 2, randomized, open-label study comparing darolutamide (DARO) vs enzalutamide (ENZA) monotherapy on serum testosterone levels in patients (pts) with castration-sensitive prostate cancer (CSPC) after biochemical recurrence (BCR)
Meeting Title:	2024 ASCO Genitourinary Cancers Symposium
Journal Title:	Journal of Clinical Oncology
Volume:	42
Issue:	4 Suppl.
Meeting Dates:	2024 Jan 25-27
Meeting Location:	San Francisco, CA
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2024-02-01
Language:	English
ACCESSION:	WOS:001266676900630
DOI:	10.1200/JCO.2024.42.4_suppl.TPS243
PROVIDER:	wos
Notes:	Meeting Abstract: TPS243 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/219721